Vireo Growth Re-Enters Ohio Through Four Concurrent Deals

MINNEAPOLIS – Vireo Growth Inc. announced that it has signed four separate Securities Purchase Agreements to acquire all membership interests of FarmaceuticalRx LLC, FarmaceuticalRx 2 LLC, CAOH LLC, and Canoe Hill Ohio, LLC. The four entities collectively bring eight dispensaries, a cultivation and processing facility, and related owned and leased real estate into Vireo’s portfolio, establishing a vertically integrated platform in Ohio from day one.

Total consideration across the four transactions is approximately $208 million, paid entirely through the issuance of roughly 11 million subordinate voting shares in three tranches. Half of the consideration is delivered at closing, one quarter approximately 90 days later, and the remainder approximately 180 days after that. Each deferred tranche is subject to a forfeiture mechanism, giving Vireo the right to claw back up to 25% of the issued shares if specified performance thresholds are not met. Closing for all four transactions is expected in Q4 2026, pending regulatory approvals in Ohio.

A disclosure embedded in the announcement warrants attention. CEO John Mazarakis holds an equity stake in CAOH LLC, one of the four acquired entities, making the Ohio package a partial related-party transaction under Canada’s Multilateral Instrument 61-101. Mazarakis has declared his conflict of interest to the board and recused himself from all deliberations and votes on the Ohio Transactions. Vireo is relying on available exemptions from formal valuation and minority shareholder approval requirements, on the basis that the related-party portion does not exceed 25% of the company’s market capitalization. A material change report is expected to be filed.

Ohio’s regulated Cannabis market has grown quickly since adult-use retail launched in August 2024. Cumulative sales across medical and adult-use channels had surpassed $3.77 billion as of late April 2026, and [monthly volumes reached $110.6 million in May 2026, up 22.5% year over year, per Headset data. The state generated more than $1 billion in combined medical and adult-use sales during its first full calendar year of adult-use operations.

The announcement lands inside a compressed M&A calendar for Vireo. The company has also disclosed plans to acquire Planet 13 Holdings, assets from The Cannabist Company across five states, FLUENT Corp., and C21 Investments, among others. Upon completion of all announced transactions, including Ohio, Vireo expects to operate approximately 270 dispensaries across 16 states.

Ohio’s retail structure is materially constrained. Roughly 209 dual-use dispensary certificates of operation were active statewide as of spring 2026, with municipal moratoriums limiting new retail access across more than 130 cities and townships. That structural tightness amplifies the value of incumbent operators, particularly those with cultivation and processing infrastructure already in position. Vireo is entering at exactly that level. The phased, performance-gated share structure reflects a disciplined approach to pricing risk in a deal that spans four separate entities. The governance wrinkle [CEO Mazarakis appearing on both sides of one of the four transactions] is the variable to watch most closely. The procedural disclosures and board recusal process appear compliant with applicable rules, but the market and regulatory reception to a CEO-as-counterparty arrangement will be a live storyline through Q4.